Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.63M Buy
29,471
+398
+1% +$21.6K 0.08% 183
2025
Q4
$1.43M Buy
29,073
+382
+1% +$17.8K 0.07% 203
2025
Q3
$1.24M Buy
28,691
+1,267
+5% +$49.5K 0.07% 205
2025
Q2
$1.05M Buy
27,424
+684
+3% +$26.1K 0.07% 201
2025
Q1
$1.04M Buy
26,740
+1,078
+4% +$39.5K 0.08% 176
2024
Q4
$868K Sell
25,662
-7,652
-23% -$275K 0.08% 179
2024
Q3
$1.36M Sell
33,314
-902
-3% -$36.9K 0.12% 130
2024
Q2
$1.32M Sell
34,216
-1,072
-3% -$45.1K 0.12% 125
2024
Q1
$1.51M Sell
35,288
-34,086
-49% -$1.41M 0.14% 107
2023
Q4
$2.57M Buy
69,374
+41,803
+152% +$1.5M 0.11% 120
2023
Q3
$999K Buy
+27,571
New +$979K 0.12% 105

Other funds holding GSK

Syon Capital's GSK Position: Q1 2026 in Review

Syon Capital increased its GSK (GSK) stake by 1.4% in Q1 2026, buying an estimated $21.6K and bringing the position to 29,471 shares worth $1.63M. The position accounts for 0.08% of the portfolio, ranked #183.

Syon Capital first reported a position in GSK in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.57M in Q4 2023. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Syon Capital held 29,471 shares of GSK worth $1.63M as of Q1 2026.
  • Syon Capital bought 398 GSK shares in Q1 2026, an estimated $21.6K.
  • GSK made up 0.08% of Syon Capital's portfolio in Q1 2026, its #183 holding.
  • Syon Capital first reported a position in GSK in Q3 2023 and has held it in 11 quarters since.
  • Syon Capital's GSK position peaked at $2.57M in Q4 2023.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Syon Capital's 13F filing for Q1 2026, filed 13 May 2026.